Skip to main content
    P

    Prelude Therapeutics Inc (PRLD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.32
    +0.09 (+2.79%)

    Market Cap: $257.76M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(17/25)
    Avg Surprise
    -47.68%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.16 - $-0.14
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.24+38.0%
    60d ago$-0.22+32.3%
    30d ago$-0.14-6.4%
    7d ago$-0.14-6.4%
    Current$-0.15
    Revenue Consensus
    $37M
    Range$5M - $100M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.03
    Range$-0.01 - $0.06
    3 analysts
    Revenue Consensus
    $7M
    Range$-16712330 - $73M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.03---
    Sep 26EST
    		-$-0.15---
    Jun 26
    Reported Aug 11
    		$-0.14$-0.17+17.65%Beat+65.9%
    Mar 26
    Reported May 12
    		$-0.13N/A+51.85%Beat+69.0%
    Dec 25
    Reported Mar 10
    		$-0.20$-0.13-53.85%Miss+45.9%
    Sep 25
    Reported Nov 12
    		$-0.26$-0.35+25.71%Beat+39.5%
    Jun 25
    Reported Aug 14
    		$-0.41$-0.43+4.65%Beat+10.9%
    Mar 25
    Reported May 6
    		$-0.42$-0.46+8.70%Beat+0.0%
    Dec 24
    Reported Mar 10
    		$-0.37$-0.47+20.82%Beat+17.8%
    Sep 24
    Reported Nov 6
    		$-0.43$-0.46+6.52%Beat+4.4%
    Jun 24
    Reported Aug 12
    		$-0.46$-0.43-6.98%Miss+14.8%
    Mar 24
    Reported May 7
    		$-0.42$-0.48+12.50%Beat+27.6%
    Dec 23
    Reported Feb 15
    		$-0.45$-0.49+8.16%Beat+25.0%
    Sep 23
    Reported Nov 1
    		$-0.45$-0.58+22.41%Beat+28.6%
    Jun 23
    Reported Aug 3
    		$-0.54$-0.63+14.29%Beat+6.9%
    Mar 23
    Reported May 8
    		$-0.58$-0.70+17.14%Beat+7.9%
    Dec 22
    Reported Mar 15
    		$-0.60$-0.63+4.76%Beat+15.5%
    Sep 22
    Reported Nov 14
    		$-0.63$-0.64+1.56%Beat+4.5%
    Jun 22
    Reported Aug 9
    		$-0.58$-0.63+7.94%Beat+0.0%
    Mar 22
    Reported May 10
    		$-0.63$-0.65+3.08%Beat-34.0%
    Dec 21
    Reported Mar 16
    		$-0.71$-0.68-4.41%Miss-57.8%
    Sep 21
    Reported Nov 12
    		$-0.66$-0.62-6.45%Miss-73.7%
    Jun 21
    Reported Aug 12
    		$-0.58$-0.49-18.37%Miss+89.5%
    Mar 21
    Reported May 11
    		$-0.47$-0.42-11.90%Miss-
    Dec 20
    Reported Mar 16
    		$-0.45$-0.47+4.26%Beat-
    Sep 20
    Reported Nov 10
    		$-0.38$-0.34-11.76%Miss-
    Jun 20
    Reported Sep 25
    		$-5.50$-0.39-1310.26%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.55EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-269.70%Operating Margin-270.90%
    ROE-57.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.07xQuick Ratio4.07x
    Trading Statistics
    Beta0.96Avg Volume517.29K
    52-Week High$6.8352-Week Low$1.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.67
    SMA 20$3.94
    SMA 50$4.84
    SMA 200$3.95
    EMA 10$3.65
    EMA 20$3.94
    EMA 50$4.39
    EMA 200$3.90

    MACD

    Line: -0.37Signal: -0.35Hist: -0.02

    ADX

    ADX: 37.8+DI: 9.3-DI: 32.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$3.79

    Bollinger Bands

    Upper Band$4.82
    Lower Band$3.07
    %B Position4445%(Upper)
    Band Width0.14

    RSI (14-Day)

    Oversold
    29.1

    Momentum Oscillators

    Stoch %K10.7
    Stoch %D13.1
    Williams %R-85.5
    ROC (10d)-12.4%
    Momentum-0.47
    CCI (20d)-138.3
    MFI (14d)42.5

    Volatility Measures

    ATR (14d)$0.30(9.2%)
    StdDev (20d)0.44
    Hist Vol70.5%(High)

    Volume Flow

    VWAP$3.32
    OBV15.9M
    AD Line22.1M
    CMF (20d)-0.038

    Volume Metrics

    Avg Vol (20d)532.7K
    Vol Ratio0.7x
    VWMA (20d)$4.00

    Pivot Points

    R3$3.71
    R2$3.61
    R1$3.42
    Pivot Point$3.31
    S1$3.12
    S2$3.02
    S3$2.83

    Advanced Oscillators

    TSI-35.61
    Ultimate Osc38.5
    KST-269.87

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.70M$4.58M$5.64M$6.50M$0$0$4.00M$3.00M$0$0$3.42M$0
    Cost of Revenue$0$0$418,000$0$0$0$489,000$0$0$0$331,000$0
    Gross Profit$5.70M$4.58M$5.64M$6.50M$0$0$4.00M$3.00M$0$0$-331,000$0
    Operating Expenses$21.16M$18.76M$22.99M$26.92M$32.19M$34.61M$37.83M$37.38M$37.16M$34.34M$37.38M$33.38M
    R&D$16.13M$13.60M$17.99M$21.71M$25.78M$28.82M$31.62M$29.46M$29.51M$27.41M$30.33M$26.26M
    SG&A$5.03M$5.16M$5.00M$5.21M$6.41M$5.79M$6.21M$7.92M$7.66M$6.93M$7.05M$7.12M
    Operating Income$-15,454,000$-14,177,000$-17,348,000$-20,418,000$-32,194,000$-34,606,000$-33,831,000$-34,376,000$-37,164,000$-34,343,000$-37,379,000$-33,385,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$6.14M$0
    Income Before Tax$-13,921,000$-10,385,000$-16,457,000$-19,725,000$-31,231,000$-32,085,000$-28,731,000$-32,271,000$-34,740,000$-31,431,000$-43,520,000$-30,608,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-13,921,000$-10,385,000$-16,457,000$-19,725,000$-31,231,000$-32,085,000$-28,731,000$-32,271,000$-34,740,000$-31,431,000$-33,075,000$-30,608,000
    EBITDA$-13,881,000$-10,382,000$-16,227,000$-19,349,000$-31,011,000$-31,571,000$-29,193,000$-32,681,000$-35,620,000$-32,546,000$-38,119,000$-31,926,000
    EBIT$-13,921,000$-10,385,000$-16,457,000$-19,725,000$-31,231,000$-32,085,000$-28,731,000$-32,271,000$-34,740,000$-31,431,000$-37,379,000$-30,608,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRLD

    News

    H.C. Wainwright keeps USD 8.00 target for Prelude Therapeutics stock

    H.C. Wainwright has reiterated its Buy rating and USD 8.00 price target for Prelude Therapeutics (PRLD) following the company's collaboration with Eli Lilly for a Phase 1 breast cancer trial. The agreement provides...

    ad-hoc-news.de•10/15/26•Bullish

    Wilmington's Prelude Therapeutics Partners With Lilly to Test KAT6A Degrader PRT13722 With Verzenio® and Inluriyo® in HR+/HER2- Breast Cancer

    Prelude Therapeutics has announced a clinical trial collaboration with Eli Lilly and Company to evaluate its oral KAT6A selective degrader, PRT13722...

    BioBuzz•10/15/26•Bullish

    H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com

    H.C. Wainwright has reiterated a Buy rating and an $8.00 price target for Prelude Therapeutics (NASDAQ: PRLD), citing significant upside potential from its current trading price of $3.56. The company recently announced...

    Investing.com Canada•10/14/26•Bullish

    Wainwright targets Prelude Therapeutics stock at USD 8.00

    H.C. Wainwright has reiterated a Buy rating for Prelude Therapeutics stock with a USD 8.00 price target, following the company's collaboration with Eli Lilly. This collaboration involves a Phase 1 trial for PRT13722...

    ad-hoc-news.de•10/13/26•Bullish

    Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

    Prelude Therapeutics has entered a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate its KAT6A selective degrader, PRT13722...

    Yahoo Finance•10/13/26•Bullish

    PRLD Valuation and Fair Value

    P/E
    -4.5x
    P/B
    2.4x
    See GNG's fair value

    PRLD Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -270.9%
    Net margin
    -269.7%
    ROE
    -57.7%
    FCF margin
    -148.3%

    PRLD Competitors

    CompanyTicker
    Palisade Bio IncPALI
    EyePoint, IncEYPT
    Standard Biotools IncLAB
    OraSure Technologies IncOSUR
    Nautilus Biotechnology IncNAUT
    Vanda Pharmaceuticals IncVNDA
    Treace Medical Concepts IncTMCI
    Inhibikase Therapeutics IncIKT

    Sector: Healthcare

    PRLD Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    2
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PRLD Bull Case vs Bear Case

    Bull case

    • PRLD beat EPS estimates in 87.5% of its last 8 reported quarters.
    • PRLD grew quarterly revenue 41.0% year over year.
    • 100.0% of PRLD's analyst ratings are Buy or Strong Buy.

    Bear case

    • PRLD has a -269.7% net profit margin.

    PRLD Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    10.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.15
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About PRLD

    Does PRLD pay dividends?

    Prelude Therapeutics Inc (PRLD) does not currently pay a regular dividend.

    What is PRLD's market cap?

    Prelude Therapeutics Inc (PRLD) has a market capitalization of $257.76M with a current stock price of $3.32.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In